These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 2856592)

  • 1. Comparative in vitro activity of imipenem and 15 other antimicrobial agents against clinically important aerobic and anaerobic bacteria.
    Goldstein EJ; Citron DM
    Clin Ther; 1988; 10(5):487-515. PubMed ID: 2856592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibacterial effect of imipenem in vitro against important aerobic and anaerobic strains isolated from clinical specimens.
    Klietmann W; Focht J; Nösner K
    Chemioterapia; 1987 Aug; 6(4):243-50. PubMed ID: 3477332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The study of drug resistance in aerobic and anaerobic bacterial flora to selected antibacterial drugs].
    Michalska W; Chylak J; Pietkiewicz K
    Med Dosw Mikrobiol; 1996; 48(1-2):61-70. PubMed ID: 8926770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimicrobial susceptibility of anaerobic and aerobic bacteria isolated from patients with mixed infections in Nicaragua.
    Cáceres M; Carrera E; Palma A; Berrios G; Weintraub A; Nord CE
    Rev Esp Quimioter; 1999 Dec; 12(4):332-9. PubMed ID: 10855012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative in vitro antimicrobial activity of a novel quinolone, garenoxacin, against aerobic and anaerobic microbial isolates recovered from general, vascular, cardiothoracic and otolaryngologic surgical patients.
    Edmiston CE; Krepel CJ; Kehl KS; Seabrook GR; Somberg LB; Almassi GH; Smith TL; Loehrl TA; Brown KR; Lewis BD; Towne JB
    J Antimicrob Chemother; 2005 Nov; 56(5):872-8. PubMed ID: 16186167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative in vitro activity of imipenem against gram-positive and gram-negative aerobic bacteria from clinical isolates.
    Bastianini L; Sposini T; Bartoli A; Marconi P
    Microbiologica; 1988 Apr; 11(2):137-42. PubMed ID: 3165489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of imipenem against gram-positive anaerobic bacteria.
    Dubreuil L; Devos J; Romond C
    Int J Clin Pharmacol Res; 1987; 7(1):39-43. PubMed ID: 3473047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ["In vitro" activity of ten antimicrobial agents against anaerobic bacteria. A collaborative study, 1999-2002].
    Litterio M; Bianchini H; Carloni G; Di Martino A; Fernández Canigia L; Greco G; Legaria C; Rollet R; Rossetti A; Predari SC; Castello L
    Rev Argent Microbiol; 2004; 36(3):130-5. PubMed ID: 15559195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Susceptibility testing of anaerobic bacteria.
    Rosenblatt JE
    Clin Lab Med; 1989 Jun; 9(2):239-54. PubMed ID: 2659243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative in vitro study of the antibacterial effect of cefotetan against gram-positive and gram-negative aerobic and anaerobic strains from fresh clinical isolates.
    Klietmann W; Focht J; Nösner K
    Chemioterapia; 1987 Jun; 6(2 Suppl):92-3. PubMed ID: 3509542
    [No Abstract]   [Full Text] [Related]  

  • 11. Antimicrobial susceptibility pattern comparisons among intensive care unit and general ward Gram-negative isolates from the Meropenem Yearly Susceptibility Test Information Collection Program (USA).
    Rhomberg PR; Fritsche TR; Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2006 Sep; 56(1):57-62. PubMed ID: 16631338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antimicrobial activity of dactimicin against aerobic and anaerobic bacteria isolated from intra-abdominal infections.
    Nord CE; Kager L
    Drugs Exp Clin Res; 1989; 15(3):113-4. PubMed ID: 2752908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of in vitro activities of levofloxacin, ciprofloxacin, ceftazidime, cefepime, imipenem, and piperacillin-tazobactam against aerobic bacterial pathogens from patients with nosocomial infections.
    Huang SS; Lee SC; Lee N; See LC; Tsai MH; Shieh WB
    J Microbiol Immunol Infect; 2007 Apr; 40(2):134-40. PubMed ID: 17446961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Susceptibility of anaerobic bacteria in Auckland: 1991-1996.
    Shore KP; Pottumarthy S; Morris AJ
    N Z Med J; 1999 Nov; 112(1099):424-6. PubMed ID: 10678225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imipenem: a new carbapenem. Committee on Antimicrobial Agents, Canadian Infectious Disease Society.
    CMAJ; 1988 Sep; 139(6):505-6. PubMed ID: 3044554
    [No Abstract]   [Full Text] [Related]  

  • 16. Antimicrobial activities of doripenem and other carbapenems against Pseudomonas aeruginosa, other nonfermentative bacilli, and Aeromonas spp.
    Castanheira M; Jones RN; Livermore DM
    Diagn Microbiol Infect Dis; 2009 Apr; 63(4):426-33. PubMed ID: 19249180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activities of dalbavancin and 12 other agents against 329 aerobic and anaerobic gram-positive isolates recovered from diabetic foot infections.
    Goldstein EJ; Citron DM; Warren YA; Tyrrell KL; Merriam CV; Fernandez HT
    Antimicrob Agents Chemother; 2006 Aug; 50(8):2875-9. PubMed ID: 16870792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations.
    Jones RN; Huynh HK; Biedenbach DJ; Fritsche TR; Sader HS
    J Antimicrob Chemother; 2004 Jul; 54(1):144-54. PubMed ID: 15190031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolution of antimicrobial susceptibility patterns of aerobic and facultative gram-negative bacilli causing intra-abdominal infections: results from the SMART studies 2003-2007.
    Guembe M; Cercenado E; Alcalá L; Marín M; Insa R; Bouza E
    Rev Esp Quimioter; 2008 Sep; 21(3):166-73. PubMed ID: 18792817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activities of doripenem and comparator agents against 364 anaerobic clinical isolates.
    Wexler HM; Engel AE; Glass D; Li C
    Antimicrob Agents Chemother; 2005 Oct; 49(10):4413-7. PubMed ID: 16189137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.